First-Line Pyrotinib Combination Therapy for HER2-Mutated Advanced NSCLC: A Retrospective Cohort Analysis.

Curr Oncol · 2025 · PMC11941541 · PMID 40136352

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although the YVMA group showed a trend toward shorter PFS (mPFS: 10.57 months vs. 13.73 months), the log-rank test analysis indicated that the difference between the two groups was not statistically significant ( p = 0.37).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.